Disclaimer: This approach to treatment is still under active investigation to confirm it is safe for patients and effective when used in conjunction with other approved therapies. We strongly discourage use of nicotine in any form, including tobacco smoking, smokeless...
CHICAGO, IL, December 19, 2017. Effective and appropriate management of chronic pain is a nation-wide priority, especially given the current US opioid crisis. The Foundation for Sarcoidosis Research, in collaboration with the Cleveland Clinic and Araim...
This year, FSR made some huge progress on our research agenda. This coming year promises to build on that progress, with new developments on several major projects that will lead to better understanding of the disease and therapies, more interest on the part of young...
The following is an excerpt from a press release by aTyr Pharma, Inc detailing their new study focusing on a potential therapy for treating interstitial lung diseases: SAN DIEGO, Nov. 27, 2017 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics...
The purpose of this study is to find out if the drug ACZ885 (Canakinumab) will improve lung function and also lower inflammation in patients with pulmonary sarcoidosis. This is a double blind study. This means neither participants nor researchers will know which...
The application for this grant period is now closed. Learn more about the CSN. The FSR-CSN is a collaborative network of sites facilitating multi-site trials and studies in sarcoidosis research. The Network is focused on highly innovative projects with the intent of...
FSR is excited to share some breaking news from the world of rare disease research that could have a huge impact on the future of diagnosing and treating rare diseases worldwide. The International Rare Diseases Research Consortium (IRDiRC) has released an ambitious...
Tracking your fitness may be a way to help manage symptoms and side effects for sarcoidosis patients. As many sarc warriors know, it can be extremely difficult to stay active when you’re living with sarc. Between the chronic pain, fatigue, shortness of breath,...
Did you know, you have access to all of your health data online? 41% of Americans have never taken advantage of their ability to see this information, and 27% reported not even being aware they had the right to! We invite you to learn more about FasterCures’ new...
The main purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. CLEAR is an acronym used to describe treatment with Combination Levofloxacin, Ethambutol,...
